A highly stable mussel mucin composition, its use, and its preparation method

Abstract

The present invention provides a stable composition containing mussel mucin, which has the characteristics of good stability, high DOPA content, and not easy to change color. The present invention also provides a preparation method of the preparation, which improves the DOPA stability of mussel mucin by adding specific components and improves the yellowing of color.

Description

Technical Field

[0001] The invention relates to the field of biomedical materials, in particular to a stable mussel mucin composition, a use thereof, and a preparation method thereof. Background Art

[0002] Mussel mucin is a protein extracted from mussels or obtained by biological fermentation. Mussel mucin contains dopa groups, which makes the protein have biological adhesion, wound healing, anti-oxidation and other functions, and has a wide range of application value in the fields of food and medicine. Therefore, it is of great application value to develop a stable preparation containing mussel mucin. Summary of the invention

[0003] The present invention provides a composition containing mussel mucin. As the storage time of a preparation containing mussel mucin increases, the dopa group in the mussel mucin will be converted into dopaquinone, thereby reducing the dopa content, causing the preparation (such as a dressing) to turn yellow, and affecting the quality of the product. At present, there are no relevant reports on research on protecting the dopa content in mussel mucin and maintaining the stability of preparations containing mussel mucin without discoloration. The mussel mucin composition proposed by the present invention has the characteristics of good stability, high dopa content, and not easy to change color. At the same time, the present invention provides a preparation method of the preparation, that is, by adding a specific component (such as butylated hydroxytoluene or sodium metabisulfite) to improve the dopa stability of mussel mucin and improve the yellowing of the color. Therefore, the high-stability mussel mucin composition of the present invention has good practical value.

[0004] In one aspect, the present invention provides a stable composition containing mussel mucin, the composition comprising:

[0005] a) 0.01 to 10%wt of mussel mucin;

[0006] b) 0.001 to 0.3%wt of component one, wherein component one is selected from one or more of uric acid, sodium pyrosulfite, propyl gallate, tri(2-carboxyethyl)phosphine, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ergothioneine, soybean lecithin, coumaric acid, and dimethyl sulfide; and

[0007] c) water;

[0008] The composition has one or more of the following characteristics:

[0009] i) After being stored at 25°C in a sealed container for three months, the appearance remains colorless; or

[0010] ii) maintaining a DOPA content in the mussel mucin of 1.2 times or more the DOPA content in the control preparation not containing the component 1 after storage at 25°C for three months.

[0011] In one aspect, the present invention provides a composition containing mussel mucin, the composition comprising:

[0012] a) 0.01 to 10%wt of mussel mucin;

[0013] b) 0.001 to 0.3%wt of component one, component one is selected from butylated hydroxytoluene (BHT) or sodium metabisulfite; and

[0014] c) Water.

[0015] In one aspect, the present invention provides a composition containing mussel mucin, the composition comprising:

[0016] a) 0.001 to 0.3%wt of component one, wherein component one is selected from one or more of uric acid, sodium pyrosulfite, propyl gallate, tri(2-carboxyethyl)phosphine, butylated hydroxytoluene, butylated hydroxyanisole, ergothioneine, soybean lecithin, coumaric acid, and dimethyl sulfide;

[0017] b) 0 to 3.0%wt of component 2, component 2 is selected from one or more of polyvinyl alcohol, xanthan gum, carbomer, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxymethylcellulose, and hydroxyethylcellulose;

[0018] c) 0.01 to 0.4%wt of component three, wherein component three is selected from one or more of benzyl alcohol, p-hydroxybenzoate, ethyl hydroxybenzoate, dimethyl fumarate, and lower fatty acid esters;

[0019] d) 1 to 20%wt of component four, component four is selected from one or more of glycerol, propylene glycol, sorbitol, glycerol, xylitol, and polyethylene glycol;

[0020] e) 0.01 to 0.3%wt of component five, wherein component five is selected from one or more of low molecular weight dextran, ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate, and sodium calcium ethylenediaminetetraacetate;

[0021] f) 0.0001 to 0.3%wt of component six, wherein component six is ​​selected from one or more of boric acid, acetic acid, pyruvic acid, citric acid, sorbic acid, DL-malic acid, DL-tartaric acid, vanillic acid, coumaric acid, gallic acid, disodium bicarbonate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and sodium hydroxide;

[0022] g) 0.01 to 10%wt mussel mucin; and

[0023] h) Water.

[0024] In one aspect, the present invention provides a topical formulation comprising the composition of any one of claims 1 to 47.

[0025] In one aspect, the present invention provides a dressing comprising the composition of any one of claims 1 to 47. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The mass ratio (%wt) of dopa to mussel mucin in the compositions of Examples 1 to 8 of the present invention after aging at 60°C for 65 days is shown. DETAILED DESCRIPTION

[0027] In one aspect, the present invention provides a stable composition containing mussel mucin, the composition comprising:

[0028] d) 0.01 to 10%wt of mussel mucin;

[0029] e) 0.001 to 0.3%wt of component one, wherein component one is selected from one or more of uric acid, sodium pyrosulfite, propyl gallate, tri(2-carboxyethyl)phosphine, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ergothioneine, soybean lecithin, coumaric acid, and dimethyl sulfide; and

[0030] f) water;

[0031] The composition has one or more of the following characteristics:

[0032] i) After being stored at 25°C in a sealed container for three months, the appearance remains colorless; or

[0033] ii) maintaining a DOPA content in the mussel mucin of 1.2 times or more the DOPA content in the control preparation not containing the component 1 after storage at 25°C for three months.

[0034] In an embodiment of the composition as described herein, component one is selected from one or more of BHT, BHA, and sodium metabisulfite. In an embodiment of the composition as described herein, component one is selected from BHT, sodium metabisulfite, or a combination of the two.

[0035] In one aspect, the present invention provides a composition containing mussel mucin, the composition comprising:

[0036] 0.01 to 10%wt mussel mucin;

[0037] 0.001 to 0.3%wt of component one, component one is selected from butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA); and water.

[0038] In an embodiment of the composition as described herein, the composition further comprises 0 to 3.0%wt of component two, and component two is selected from one or more of polyvinyl alcohol, xanthan gum, carbomer, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, hydroxymethyl cellulose, and hydroxyethyl cellulose.

[0039] In an embodiment of the composition as described herein, the composition further comprises 0.01 to 0.4%wt of component three, and component three is selected from one or more of benzyl alcohol, parabens, ethyl hydroxybenzoate, dimethyl fumarate, and lower fatty acid esters.

[0040] In an embodiment of the composition as described herein, the composition further comprises 1 to 20%wt of component four, and component four is selected from one or more of glycerol, propylene glycol, sorbitol, glycerol, xylitol, and polyethylene glycol.

[0041] In an embodiment of the composition as described herein, the composition further comprises 0.01 to 0.3%wt of component five, and component five is selected from one or more of low molecular weight dextran, ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate, and sodium calcium ethylenediaminetetraacetate.

[0042] In an embodiment of the composition as described herein, the composition further comprises 0.0001 to 0.3%wt of component six, and component six is ​​selected from one or more of boric acid, acetic acid, pyruvic acid, citric acid, sorbic acid, DL-malic acid, DL-tartaric acid, vanillic acid, coumaric acid, gallic acid, disodium bicarbonate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and sodium hydroxide.

[0043] In one aspect, the present invention provides a composition containing mussel mucin, the composition comprising:

[0044] 0.001 to 0.3%wt of component one, wherein component one is selected from one or more of uric acid, sodium pyrosulfite, propyl gallate, tri(2-carboxyethyl)phosphine, butylated hydroxytoluene, butylated hydroxyanisole, ergothioneine, soybean lecithin, coumaric acid, dimethyl sulfide, and 3-O-ethyl ascorbic acid ether;

[0045] 0 to 3.0%wt of component 2, component 2 is selected from one or more of polyvinyl alcohol, xanthan gum, carbomer, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, hydroxymethyl cellulose, and hydroxyethyl cellulose;

[0046] 0.01 to 0.4%wt of component three, component three is selected from one or more of benzyl alcohol, p-hydroxybenzoate, ethyl hydroxybenzoate, dimethyl fumarate, and lower fatty acid esters;

[0047] 1 to 20%wt of component four, component four is selected from one or more of glycerol, propylene glycol, sorbitol, glycerol, xylitol, and polyethylene glycol;

[0048] 0.01 to 0.3%wt of component five, wherein component five is selected from one or more of low molecular weight dextran, ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate, and sodium calcium ethylenediaminetetraacetate;

[0049] 0.0001 to 0.3%wt of component six, component six is ​​selected from one or more of boric acid, acetic acid, pyruvic acid, citric acid, sorbic acid, DL-malic acid, DL-tartaric acid, vanillic acid, coumaric acid, gallic acid, disodium bicarbonate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and sodium hydroxide;

[0050] 0.01 to 10%wt of mussel mucin; and water.

[0051] In an embodiment of the composition as described herein, the composition further comprises 0.01 to 0.5%wt of component seven, and component seven is selected from one or more of polysorbate 80, calcium stearate, aluminum monostearate, dimethicone, disodium hydrogen phosphate dodecahydrate, dipotassium hydrogen phosphate trihydrate, soybean lecithin, sodium alginate, poloxamer, polysorbate 20, egg yolk lecithin, gum arabic, caprylic and capric mono- and di-glycerides, oleic acid, mono- and distearic glycerides, potassium stearate, sodium citrate, sodium stearate, sorbitan oleate (Span 80), polyoxyethylene 35 castor oil, cetostearyl alcohol, lanolin, stearyl alcohol, cetyl alcohol, and cholesterol.

[0052] In an embodiment of the composition as described herein, the composition further comprises 0.0001 to 0.3%wt of component eight, and component eight is selected from one or more of carotene, chlorophyll, lutein ester, and lutein.

[0053] In an embodiment of the composition as described herein, the component one comprises BHT. In an embodiment of the composition as described herein, wherein the component one comprises BHA. In an embodiment of the composition as described herein, wherein the component one comprises sodium metabisulfite.

[0054] In an embodiment of the composition as described herein, the composition comprises mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.001 to 20%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.001 to 10%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.01 to 10%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.01 to 5%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.01 to 1%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.01 to 0.1%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.05 to 1%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.05 to 5%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 1 to 5%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 1 to 10%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 5 to 10%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.01%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.02%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.03%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.04%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.05%wt of mussel mucin. In an embodiment of the composition as described herein, the composition comprises 0.1%wt of mussel mucin.

[0055] In an embodiment of the composition as described herein, the composition comprises component one. The component one includes uric acid, sodium pyrosulfite, propyl gallate, tri(2-carboxyethyl)phosphine, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ergothioneine, soybean lecithin, coumaric acid, or dimethyl sulfide, or a combination of multiple thereof. In some embodiments, the composition comprises 0.001 to 0.5%wt of component one. In some embodiments, the composition comprises 0.001 to 0.3%wt of component one. In some embodiments, the composition comprises 0.001 to 0.2%wt of component one. In some embodiments, the composition comprises 0.001 to 0.1%wt of component one. In some embodiments, the composition comprises 0.001 to 0.01%wt of component one. In some embodiments, the composition comprises 0.001 to 0.02%wt of component one. In some embodiments, the composition comprises 0.001 to 0.03%wt of component one. In some embodiments, the composition comprises 0.001 to 0.04%wt of component one. In some embodiments, the composition comprises 0.001 to 0.05%wt of component one. In some embodiments, the composition comprises 0.005 to 0.1%wt of component one. In some embodiments, the composition comprises 0.01 to 0.1%wt of component one. In some embodiments, the composition comprises 0.01 to 0.03%wt of component one. In some embodiments, the composition comprises 0.01 to 0.05%wt of component one. In some embodiments, the composition comprises 0.01 to 0.08%wt of component one. In some embodiments, the composition comprises 0.01 to 0.2%wt of component one. In some embodiments, the composition comprises 0.01 to 0.3%wt of component one. In some embodiments, the composition comprises 0.01%wt of component one. In some embodiments, the composition comprises 0.02%wt of component one. In some embodiments, the composition comprises 0.03%wt of component one. In some embodiments, the composition comprises 0.04%wt of component one. In some embodiments, the composition comprises 0.05%wt of component one. In some embodiments, the component one comprises butylated hydroxytoluene (BHT). In some embodiments, the component one comprises butylated hydroxyanisole (BHA). In some embodiments, the component one comprises sodium pyrosulfite. In some embodiments, the component one comprises BHT, BHA, or sodium pyrosulfite. In some embodiments, the component one comprises BHT or sodium pyrosulfite.

[0056] In an embodiment of the composition as described herein, the composition comprises 0.001 to 0.3%wt of BHT. In some embodiments, the composition comprises 0.001 to 0.2%wt of BHT. In some embodiments, the composition comprises 0.001 to 0.1%wt of BHT. In some embodiments, the composition comprises 0.001 to 0.01%wt of BHT. In some embodiments, the composition comprises 0.001 to 0.02%wt of BHT. In some embodiments, the composition comprises 0.001 to 0.03%wt of BHT. In some embodiments, the composition comprises 0.001 to 0.04%wt of BHT. In some embodiments, the composition comprises 0.001 to 0.05%wt of BHT. In some embodiments, the composition comprises 0.005 to 0.1%wt of BHT. In some embodiments, the composition comprises 0.01 to 0.1%wt of BHT. In some embodiments, the composition comprises 0.01 to 0.03%wt of BHT. In some embodiments, the composition comprises 0.01 to 0.05%wt of BHT. In some embodiments, the composition comprises 0.01 to 0.08%wt of BHT. In some embodiments, the composition comprises 0.01 to 0.2%wt of BHT. In some embodiments, the composition comprises 0.01 to 0.3%wt of BHT. In some embodiments, the composition comprises 0.01%wt of BHT. In some embodiments, the composition comprises 0.02%wt of BHT. In some embodiments, the composition comprises 0.03%wt of BHT. In some embodiments, the composition comprises 0.04%wt of BHT. In some embodiments, the composition comprises 0.05%wt of BHT.

[0057] In an embodiment of the composition as described herein, the composition comprises 0.001 to 0.3%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.001 to 0.2%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.001 to 0.1%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.001 to 0.01%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.001 to 0.02%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.001 to 0.03%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.001 to 0.04%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.001 to 0.05%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.005 to 0.1%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.01 to 0.1%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.01 to 0.03%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.01 to 0.05%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.01 to 0.08%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.01 to 0.2%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.01 to 0.3%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.01%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.02%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.03%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.04%wt of sodium pyrosulfite. In some embodiments, the composition comprises 0.05%wt of sodium pyrosulfite.

[0058] In embodiments of the composition as described herein, the ratio (wt / wt) of the mussel mucin to the component one is 100:1 to 1:100. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 50:1 to 1:50. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 40:1 to 1:40. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 30:1 to 1:30. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 20:1 to 1:20. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 10:1 to 1:20. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:1 to 1:20. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:1 to 1:10. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:1 to 1:5. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:1 to 1:1. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:1. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:2. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:3. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 5:4. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 1:1. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 2:3. In some embodiments, the ratio (wt / wt) of the mussel mucin to the component one is 1:2.

[0059] In an embodiment of the composition as described herein, the composition comprises component two. In some embodiments, the component two comprises polyvinyl alcohol, xanthan gum, carbomer, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxymethylcellulose, or hydroxyethylcellulose. In some embodiments, the component two comprises hydroxyethylcellulose. In some embodiments, the component two comprises xanthan gum. In some embodiments, the component two comprises carbomer. In some embodiments, the component two comprises hydroxypropyl methylcellulose. In some embodiments, the component two comprises polyvinyl alcohol. In some embodiments, the composition comprises 0.1 to 2.0%wt component two. In some embodiments, the composition comprises 0.1 to 1.5%wt component two. In some embodiments, the composition comprises 0.1 to 1.0%wt component two. In some embodiments, the composition comprises 0.5 to 1.0%wt component two. In some embodiments, the composition comprises 0.5 to 1.5%wt component two. In some embodiments, the composition comprises 0.5 to 2.0%wt component two. In some embodiments, the composition comprises 0.1 to 0.5%wt component two. In some embodiments, the composition comprises 0.1 to 1%wt component two. In some embodiments, the composition comprises 0.7%wt component two. In some embodiments, the composition comprises 0.1 to 2.0%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.1 to 1.5%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.1 to 1.0%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.5 to 1.0%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.5 to 1.5%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.5 to 2.0%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.1 to 0.5%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.1 to 1%wt hydroxyethyl cellulose. In some embodiments, the composition comprises 0.7%wt hydroxyethyl cellulose.

[0060] In an embodiment of the composition as described herein, the composition comprises component three. In some embodiments, the component three comprises benzyl alcohol, parabens, ethyl hydroxybenzoate, dimethyl fumarate, or a lower fatty acid ester. In some embodiments, the component three comprises parabens. In some embodiments, the component three comprises methyl paraben. In some embodiments, the component three comprises ethyl paraben. In some embodiments, the component three comprises propyl paraben. In some embodiments, the component three comprises butyl paraben. In some embodiments, the composition comprises 0.01 to 1.0%wt component three. In some embodiments, the composition comprises 0.01 to 0.5%wt component three. In some embodiments, the composition comprises 0.01 to 0.4%wt component three. In some embodiments, the composition comprises 0.01 to 0.1%wt component three. In some embodiments, the composition comprises 0.01 to 0.05%wt component three. In some embodiments, the composition comprises 0.01%wt component three. In some embodiments, the composition comprises 0.02%wt component three. In some embodiments, the composition comprises 0.03%wt component three. In some embodiments, the composition comprises 0.04%wt component three. In some embodiments, the composition comprises 0.05%wt component three. In some embodiments, the composition comprises 0.1%wt component three. In some embodiments, the composition comprises 0.01 to 1.0%wt parabens. In some embodiments, the composition comprises 0.01 to 0.5%wt parabens. In some embodiments, the composition comprises 0.01 to 0.1%wt parabens. In some embodiments, the composition comprises 0.01 to 0.05%wt parabens. In some embodiments, the composition comprises 0.01%wt parabens. In some embodiments, the composition comprises 0.02%wt parabens. In some embodiments, the composition comprises 0.03%wt parabens. In some embodiments, the composition comprises 0.04% wt paraben. In some embodiments, the composition comprises 0.05% wt paraben. In some embodiments, the composition comprises 0.1% wt paraben.

[0061] In an embodiment of the composition as described herein, the composition comprises component four. In some embodiments, the component four comprises one or more of glycerol, propylene glycol, sorbitol, glycerol, xylitol, and polyethylene glycol. In some embodiments, the component four comprises one or more of glycerol, propylene glycol, xylitol, and polyethylene glycol. In some embodiments, the component four comprises glycerol. In some embodiments, the component four comprises propylene glycol. In some embodiments, the component four comprises glycerol and propylene glycol. In some embodiments, the component four comprises xylitol. In some embodiments, the component four comprises glycerol and xylitol. In some embodiments, the component four comprises polyethylene glycol. In some embodiments, the component four comprises glycerol, propylene glycol, xylitol, and polyethylene glycol. In some embodiments, the composition comprises 0.1 to 50%wt component four. In some embodiments, the composition comprises 1 to 40%wt component four. In some embodiments, the composition comprises 1 to 30%wt component four. In some embodiments, the composition comprises 1 to 25%wt component four. In some embodiments, the composition comprises 1 to 20%wt component tetra. In some embodiments, the composition comprises 1 to 15%wt component tetra. In some embodiments, the composition comprises 1 to 30%wt component tetra. In some embodiments, the composition comprises 1 to 10%wt component tetra. In some embodiments, the composition comprises 0.1 to 5%wt component tetra. In some embodiments, the composition comprises 5 to 10%wt component tetra. In some embodiments, the composition comprises 10 to 15%wt component tetra. In some embodiments, the composition comprises 15 to 20%wt component tetra. In some embodiments, the composition comprises 20 to 30%wt component tetra. In some embodiments, the composition comprises 30 to 40%wt component tetra. In some embodiments, the composition comprises 40 to 50%wt component tetra. In some embodiments, the composition comprises 1%wt component tetra. In some embodiments, the composition comprises 5%wt component tetra. In some embodiments, the composition comprises 9%wt component tetra. In some embodiments, the composition comprises 10%wt component tetra. In some embodiments, the composition comprises 15%wt component four. In some embodiments, the composition comprises 20%wt component four. In some embodiments, the composition comprises 25%wt component four. In some embodiments, the composition comprises 30%wt component four. In some embodiments, the composition comprises 40%wt component four. In some embodiments, the composition comprises 50%wt component four. In some embodiments, the composition comprises 9%wt component four, and the component four comprises glycerol, propylene glycol, xylitol, and polyethylene glycol.

[0062] In an embodiment of the composition as described herein, the composition comprises component five. In some embodiments, the component five comprises low molecular weight dextran, ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate, or sodium calcium ethylenediaminetetraacetate. In some embodiments, the component five comprises disodium ethylenediaminetetraacetate. In some embodiments, the composition comprises 0.01 to 0.3%wt component five. In some embodiments, the composition comprises 0.01 to 0.1%wt component five. In some embodiments, the composition comprises 0.01 to 0.2%wt component five. In some embodiments, the composition comprises 0.01 to 0.25%wt component five. In some embodiments, the composition comprises 0.1 to 0.2%wt component five. In some embodiments, the composition comprises 0.2 to 0.3%wt component five. In some embodiments, the composition comprises 0.1%wt component five. In some embodiments, the composition comprises 0.01 to 0.3%wt disodium ethylenediaminetetraacetate. In some embodiments, the composition comprises 0.01 to 0.1%wt disodium ethylenediaminetetraacetate. In some embodiments, the composition comprises 0.01 to 0.2%wt disodium ethylenediaminetetraacetate. In some embodiments, the composition comprises 0.01 to 0.25%wt disodium ethylenediaminetetraacetate. In some embodiments, the composition comprises 0.1 to 0.2%wt disodium ethylenediaminetetraacetate. In some embodiments, the composition comprises 0.2 to 0.3%wt disodium ethylenediaminetetraacetate. In some embodiments, the composition comprises 0.1%wt disodium ethylenediaminetetraacetate.

[0063] In an embodiment of the composition as described herein, the composition comprises component six. In some embodiments, the composition comprises 0.0001 to 0.3%wt of component six. In some embodiments, the component six is ​​selected from one or more of boric acid, acetic acid, pyruvic acid, citric acid, sorbic acid, DL-malic acid, DL-tartaric acid, vanillic acid, coumaric acid, gallic acid, disodium bicarbonate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and sodium hydroxide. In some embodiments, the component six comprises DL-malic acid. In some embodiments, the composition comprises 0.001 to 0.1%wt of component six. In some embodiments, the composition comprises 0.1 to 0.2%wt of component six. In some embodiments, the composition comprises 0.2 to 0.3%wt of component six. In some embodiments, the composition comprises 0.0001 to 0.2%wt of component six. In some embodiments, the composition comprises 0.0001 to 0.1%wt of component six. In some embodiments, the composition comprises 0.0001 to 0.05%wt of component six. In some embodiments, the composition comprises 0.0001 to 0.01%wt of component six. In some embodiments, the composition comprises 0.0001 to 0.005%wt of component six. In some embodiments, the composition comprises 0.0005 to 0.1%wt of component six. In some embodiments, the composition comprises 0.0005 to 0.05%wt of component six. In some embodiments, the composition comprises 0.0005 to 0.01%wt of component six. In some embodiments, the composition comprises 0.001 to 0.1%wt of component six. In some embodiments, the composition comprises 0.001 to 0.05%wt of component six. In some embodiments, the composition comprises 0.001 to 0.01%wt of component six. In some embodiments, the composition comprises 0.001 to 0.003%wt of component six. In some embodiments, the composition comprises 0.001 to 0.002%wt component six. In some embodiments, the composition comprises 0.001%wt component six. In some embodiments, the composition comprises 0.002%wt component six. In some embodiments, the composition comprises 0.003%wt component six. In some embodiments, the composition comprises 0.0013%wt component six. In some embodiments, the composition comprises 0.001 to 0.1%wt DL-malic acid. In some embodiments, the composition comprises 0.1 to 0.2%wt DL-malic acid. In some embodiments, the composition comprises 0.2 to 0.3%wt DL-malic acid. In some embodiments, the composition comprises 0.0001 to 0.2%wt DL-malic acid.In some embodiments, the composition comprises 0.0001 to 0.1%wt of DL-malic acid. In some embodiments, the composition comprises 0.0001 to 0.05%wt of DL-malic acid. In some embodiments, the composition comprises 0.0001 to 0.01%wt of DL-malic acid. In some embodiments, the composition comprises 0.0001 to 0.005%wt of DL-malic acid. In some embodiments, the composition comprises 0.0005 to 0.1%wt of DL-malic acid. In some embodiments, the composition comprises 0.0005 to 0.05%wt of DL-malic acid. In some embodiments, the composition comprises 0.0005 to 0.01%wt of DL-malic acid. In some embodiments, the composition comprises 0.001 to 0.1%wt of DL-malic acid. In some embodiments, the composition comprises 0.001 to 0.05%wt of DL-malic acid. In some embodiments, the composition comprises 0.001 to 0.01% wt DL-malic acid. In some embodiments, the composition comprises 0.001 to 0.003% wt DL-malic acid. In some embodiments, the composition comprises 0.001 to 0.002% wt DL-malic acid. In some embodiments, the composition comprises 0.001 to 0.0013% wt DL-malic acid.

[0064] In an embodiment of the composition as described herein, the composition comprises component seven. In some embodiments, the composition further comprises 0.01 to 0.5%wt of component seven. In some embodiments, component seven is selected from polysorbate 80, calcium stearate, aluminum monostearate, dimethicone, disodium hydrogen phosphate dodecahydrate, dipotassium hydrogen phosphate trihydrate, soybean lecithin, sodium alginate, poloxamer, polysorbate 20, egg yolk lecithin, gum arabic, caprylic acid capric acid mono- and di-glycerides, oleic acid, mono- and di-stearic acid glycerides, potassium stearate, sodium citrate, sodium stearate, sorbitan oleate (Span 80), polyoxyethylene 35 castor oil, cetostearyl alcohol, lanolin, octadecyl alcohol, hexadecanol, one or more of cholesterol.

[0065] In an embodiment of the composition as described herein, the composition comprises component eight. In some embodiments, the component eight comprises carotene, chlorophyll, lutein ester, or lutein. In some embodiments, the component eight comprises lutein ester. In some embodiments, the composition comprises 0.0001 to 0.3%wt of component eight. In some embodiments, the composition comprises 0.0001 to 0.1%wt of component eight. In some embodiments, the composition comprises 0.001 to 0.1%wt of component eight. In some embodiments, the composition comprises 0.01 to 0.1%wt of component eight. In some embodiments, the composition comprises 0.01 to 0.1%wt of component eight. In some embodiments, the composition comprises 0.01 to 0.05%wt of component eight. In some embodiments, the component eight comprises 0.02%wt of lutein ester.

[0066] In embodiments of the compositions as described herein, the pH of the composition is between 2.0 and 9.0. In embodiments of the compositions as described herein, the pH of the composition is between 2.0 and 8.0. In embodiments of the compositions as described herein, the pH of the composition is between 3.0 and 7.0. In some embodiments, the pH of the composition is between 3.5 and 6.5. In some embodiments, the pH of the composition is between 3.5 and 6.0. In some embodiments, the pH of the composition is between 3.5 and 5.5. In some embodiments, the pH of the composition is between 3.5 and 5.0. In some embodiments, the pH of the composition is between 4.0 and 5.0. In some embodiments, the pH of the composition is between 4.5 and 5.5. In some embodiments, the pH of the composition is between 4.5 and 5.0. In some embodiments, the pH of the composition is between 4.0 and 6.0. In some embodiments, the pH of the composition is between 3.5 and 5.0. In some embodiments, the pH of the composition is between 3.0. In some embodiments, the pH of the composition is between 3.5 and 5.0. In some embodiments, the pH value of the composition is 3.5. In some embodiments, the pH value of the composition is 3.5 to 5.0. In some embodiments, the pH value of the composition is 4.0. In some embodiments, the pH value of the composition is 3.5 to 5.0. In some embodiments, the pH value of the composition is 4.5. In some embodiments, the pH value of the composition is 3.5 to 5.0. In some embodiments, the pH value of the composition is 4.75. In some embodiments, the pH value of the composition is 3.5 to 5.0. In some embodiments, the pH value of the composition is 4.9. In some embodiments, the pH value of the composition is 4.8. In some embodiments, the pH value of the composition is 4.85. In some embodiments, the pH value of the composition is 5.0.

[0067] In the embodiments of the composition as described herein, the mussel mucin can be mussel mucin from any source, and can be synthetic mussel mucin, recombinant mussel mucin or extracted from mussels.

[0068] In some embodiments, the mussel mucin is extracted from mussels. The mussel mucin extracted from mussels can be obtained by, but is not limited to, the following preparation methods, such as a method for purifying mussel mucin using mixed adsorption chromatography separation and purification in Chinese Patent No. ZL200710179491.0, a method for purifying mussel mucin using carboxymethyl ion exchange chromatography in Chinese Patent No. ZL200710179492.5, a method for purifying mussel mucin using salting out and dialysis separation and purification in Chinese Patent No. ZL200910087567.6, etc.

[0069] In some embodiments, the mussel mucin is a recombinant mussel mucin. The recombinant mussel mucin can be obtained by conventional or known recombinant protein technology. For example, the mussel mucin can be obtained by the method mentioned in the following report: Chinese Patent No.

[0070] CN115894655A, U.S. Patent No. US6987170B1, and U.S. Patent Publication No. US2016030323A.

[0071] In some embodiments, the mussel mucin is a synthetic mussel mucin. Synthetic mussel mucin can be obtained by methods that have been reported, such as those reported in Kitamura et al., J. Polymer Science: Part A: Polymer Chemistry 37: 729-736 (1991); Lim et al., Biomaterials, 31: 3715-3722 (2010), and Hwang et al., Biomaterials 28: 3560-3568 (2007).

[0072] In some embodiments, the mussel mucin can be obtained through commercial channels, such as Cell-Tek (Catalog No. 354240) and ACRO Biosystems (Catalog No. MAP-04012).

[0073] In some embodiments, the mussel mucin comprises one or more of Mfp-1, Mfp-2, Mfp-3, Mfp-4, Mfp-5, and Mfp-6. In some embodiments, the mussel mucin comprises Mfp-1. In some embodiments, the mussel mucin comprises Mfp-2. In some embodiments, the mussel mucin comprises Mfp-3. In some embodiments, the mussel mucin comprises Mfp-4. In some embodiments, the mussel mucin comprises Mfp-5. In some embodiments, the mussel mucin comprises Mfp-6.

[0074] In some embodiments, the mussel mucin is derived from Mytilus edulis (ie, Mefp), Mytilus galloprovincialis (ie, Mgfp), Mytlilus coruscus (ie, Mufp), Pernaviridis, Mytlilus californianus (ie, Mcfp), or Limnoperna fortune. In some embodiments, the mussel mucin is derived from Mytilus edulis (ie, Mefp). In some embodiments, the mussel mucin is derived from Mytilus galloprovincialis (ie, Mgfp). In some embodiments, the mussel mucin is derived from Mytlilus coruscus (ie, Mufp). In some embodiments, the mussel mucin is derived from Perna viridis. In some embodiments, the mussel mucin is derived from Mytlilus californianus (ie, Mcfp). In some embodiments, the mussel mucin is derived from or Limnoperna fortune.

[0075] In some embodiments, the mussel mucin comprises one or more of Mefp-1, Mefp-2, Mefp-3, Mefp-4, Mefp-5, Mefp-6, Mcfp-1, Mcfp-2, Mcfp-3, Mcfp-4, Mcfp-5, Mcfp-6, Mgfp-1, Mgfp-2, Mgfp-3, Mgfp-4, Mgfp-5, Mgfp-6, Mufp-1, Mufp-2, Mufp-3, Mufp-4, Mufp-5, and Mufp-6.

[0076] In some embodiments, the mussel mucin comprises a fused mussel mucin. The fused mussel mucin described herein comprises two, three, or more of Mfp-1, Mfp-2, Mfp-3, Mfp-4, Mfp-5, and Mfp-6. The fused mussel mucin described herein may include the fused mussel mucin disclosed in WO2006 / 107183 and WO2005 / 092920. Preferably, the mussel mucin may include fused mussel mucin, such as (from N-terminus to C-terminus) Mfp-1 fragment-Mfp-5 fragment-Mfp-1 fragment (ie, fp-151), Mfp-1 fragment-Mfp-3 fragment-Mfp-1 fragment (ie, fp-131), Mfp-3 fragment-Mfp-5 fragment-Mfp-3 fragment (ie, fp-353), Mfp-1 fragment-Mfp-5 fragment-Mfp-3 fragment (ie, fp-153), Mfp-3 fragment-Mfp-5 fragment-Mfp-1 fragment (ie, fp-351), etc., but are not limited thereto.

[0077] In some embodiments, the mussel mucin comprises a mussel mucin fragment. The mussel mucin fragment may comprise 1% to 10%, 10% to 20%, 20% to 30%, 30% to 40%, 40% to 50%, 50% to 60%, 60% to 70%, 70% to 80%, 80% to 90%, 90% to 99% of the amino acid sequence of the complete mussel mucin.

[0078] In some embodiments, the mussel mucin may be selected from Table 7.

[0079] Table 7. Different types and sources of mussel mucin

[0080]

[0081]

[0082] In an embodiment of the composition as described herein, the mussel mucin composition can maintain good stability. The stability of the mussel mucin composition can be reflected by measuring or observing the color change of the composition. In some embodiments, the stable composition has the characteristic of being colorless or light yellow in appearance. The stability of the mussel mucin composition can be reflected by measuring the content of DOPA in the composition. The content of DOPA in the mussel mucin composition can be determined by the method described in Example 9. In an embodiment of the composition as described herein, the composition has one or more of the following characteristics: i) the appearance color remains colorless after being stored for three months under sealed storage conditions at 25°C; or ii) the content of DOPA in the mussel mucin is maintained at 1.2 times or more of the content of DOPA in the control preparation not containing component one described herein after being stored for three months under sealed storage conditions at 25°C.

[0083] In some embodiments, the composition maintains a colorless appearance after being stored for one month under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for 65 days under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for two months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for three months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for four months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for five months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for six months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for nine months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for twelve months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after being stored for eighteen months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after storage for twenty-four months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless or light yellow appearance after storage for six months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless or light yellow appearance after storage for nine months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless or light yellow appearance after storage for twelve months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless or light yellow appearance after storage for eighteen months under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless or light yellow appearance after storage for twenty-four months under a sealed storage condition at 25°C.

[0084] In some embodiments, the composition maintains a colorless appearance after being stored for two weeks under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless appearance after being stored for one month under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless appearance after being stored for 65 days under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless appearance after being stored for two months under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless appearance after being stored for three months under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless appearance after being stored for four months under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless appearance after being stored for five months under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless appearance after being stored for six months under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless or light yellow appearance after being stored for one month under a sealed storage condition at 40°C. In some embodiments, the composition maintains a colorless or light yellow appearance after being stored for two months under a sealed storage condition at 40°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for three months under a sealed storage condition at 40°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for four months under a sealed storage condition at 40°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for five months under a sealed storage condition at 40°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for six months under a sealed storage condition at 40°C.

[0085] In some embodiments, the composition maintains a colorless appearance after being stored for one week under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless appearance after being stored for two weeks under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless appearance after being stored for three weeks under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless appearance after being stored for one month under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless appearance after being stored for 65 days under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless appearance after being stored for two months under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless appearance after being stored for three months under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless or light yellow appearance after being stored for one week under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless or light yellow appearance after being stored for two weeks under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless or light yellow appearance after being stored for three weeks under a sealed storage condition at 60°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for one month under a sealed storage condition at 60°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for 65 days under a sealed storage condition at 60°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for two months under a sealed storage condition at 60°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after being stored for three months under a sealed storage condition at 60°C.

[0086] In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.1 times or more of the DOPA content in a control formulation without component one after storage for one month under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.2 times or more of the DOPA content in a control formulation without component one after storage for 65 days under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.2 times or more of the DOPA content in a control formulation without component one after storage for two months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.2 times or more of the DOPA content in a control formulation without component one after storage for three months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.2 times or more of the DOPA content in a control formulation without component one after storage for four months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin of 1.2 times or more of the DOPA content in a control formulation without component one after storage for five months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin of 1.5 times or more of the DOPA content in a control formulation without component one after storage for six months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin of 2 times or more of the DOPA content in a control formulation without component one after storage for nine months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin of 2 times or more of the DOPA content in a control formulation without component one after storage for twelve months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin of 2 times or more of the DOPA content in a control formulation without component one after storage for eighteen months under sealed storage conditions at 25°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after storage for twenty-four months at 25°C under sealed storage conditions. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for six months at 25°C under sealed storage conditions. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for nine months at 25°C under sealed storage conditions. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for twelve months at 25°C under sealed storage conditions.In some embodiments, the composition maintains a DOPA content in mussel mucin of 1.5 times or more than the DOPA content in a control formulation without component 1 after storage for eighteen months at 25°C under sealed storage conditions. In some embodiments, the composition maintains a DOPA content in mussel mucin of 1.5 times or more than the DOPA content in a control formulation without component 1 after storage for twenty-four months at 25°C under sealed storage conditions.

[0087] In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored for two weeks under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored for one month under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored for 65 days under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored for two months under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored for three months under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after storage for four months under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after storage for five months under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after storage for six months under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for one month under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for two months under sealed storage conditions at 40°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for three months at 40°C sealed storage conditions. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for four months at 40°C sealed storage conditions. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for five months at 40°C sealed storage conditions. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for six months at 40°C sealed storage conditions.

[0088] In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored under sealed storage conditions at 60°C for one week. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored under sealed storage conditions at 60°C for two weeks. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored under sealed storage conditions at 60°C for three weeks. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored under sealed storage conditions at 60°C for one month. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored under sealed storage conditions at 60°C for 65 days. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored for two months under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after being stored for three months under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after being stored for one week under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after being stored for two weeks under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after being stored for three weeks under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for one month under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for 65 days under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for two months under a sealed storage condition at 60°C. In some embodiments, the composition maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for three months under a sealed storage condition at 60°C.

[0089] In some embodiments, the composition maintains a colorless appearance after i) three months of storage under a sealed storage condition at 25°C; or ii) maintains a 1.2-fold or higher DOPA content in the mussel mucin compared to the DOPA content in the control formulation without component one after three months of storage under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after three months of storage under a sealed storage condition at 25°C and maintains a 2-fold or higher DOPA content in the mussel mucin compared to the DOPA content in the control formulation without component one. In some embodiments, the composition maintains a colorless appearance after i) three months of storage under a sealed storage condition at 25°C; or ii) 1.5-fold or higher DOPA content in the mussel mucin compared to the DOPA content in the control formulation without component one after six months of storage under a sealed storage condition at 25°C. In some embodiments, the composition maintains a colorless appearance after three months of storage under a sealed storage condition at 25°C and maintains a 2-fold or higher DOPA content in the mussel mucin compared to the DOPA content in the control formulation without component one. In some embodiments, the composition i) maintains an appearance color of colorless or light yellow after storage for 65 days under a sealed storage condition at 40°C; or ii) maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for 65 days under a sealed storage condition at 40°C. In some embodiments, the composition maintains an appearance color of colorless or light yellow after storage for 65 days under a sealed storage condition at 40°C and maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component one after storage for 65 days under a sealed storage condition at 40°C. In some embodiments, the composition i) maintains an appearance color of colorless or light yellow after storage for 65 days under a sealed storage condition at 60°C; or ii) maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component one after storage for 65 days under a sealed storage condition at 60°C. In some embodiments, the composition maintains a colorless or light yellow appearance after storage for 65 days at 60° C. under sealed storage conditions, and maintains a DOPA content in mussel mucin that is 1.5 times or more of the DOPA content in a control formulation without component 1. In some embodiments, the composition maintains a light yellow appearance after storage for 65 days at 60° C. under sealed storage conditions, and maintains a DOPA content in mussel mucin that is 2 times or more of the DOPA content in a control formulation without component 1.

[0090] In some embodiments, the control formulation has the same ingredients as the mussel mucin composition except that it does not contain component one, such as the blank control in the examples.

[0091] In one aspect, the present invention provides a topical preparation comprising any of the compositions described above. In an embodiment of a topical preparation as described herein, the topical preparation is a solution, a hydrogel, a cream, a paste, an emulsion, an ointment, a foam, an essence, or a moisturizer. In an embodiment of a topical preparation as described herein, the topical preparation is used for the epidermis. As used herein, a topical preparation comprises any form of preparation that can be directly applied to the epidermis, an epidermal wound, and optionally a preparation around the wound area next to the epidermal wound. As used herein, "epidermis" refers to one or more outer protective layers of both the skin membrane and the mucous membrane of a biological organism, and the term "epidermis wound" refers to the rupture and loss of at least a portion of the epidermis (including one or more outermost sublayers of the epidermis, i.e., the epidermis), and optionally the destruction of deep tissues (such as dermis, fat, fascia connective tissue) and muscles and bones. Epidermis wounds may include wounds commonly referred to as open wounds (also referred to as wound beds), in which the damaged body area exposes the dermis layer of the skin or one or more tissues and one or more structures (such as fat, muscle, fascia and bone) under the dermis layer of the skin to air. As will be appreciated by those skilled in the art, the epidermis has two major layers: (i) an outer layer, called the epidermis, which acts as a barrier to the external environment, and (ii) an inner layer, called the dermis, which is composed of connective tissue and provides some of the mechanical properties of the skin. In some embodiments, epidermal wounds include wounds formed after cosmetic or surgical procedures.

[0092] In some embodiments, the topical preparation provided herein may include a liquid carrier, which is selected for instilling the topical preparation into a skin wound, a wound peri-region beside a skin wound, or both. As used herein, "liquid carrier" is generally understood to include any carrier that is liquid at ambient temperature and that one or more activating agents are carried, dispersed in, or dissolved therein. The liquid carrier can be in the form of a viscous liquid, a paste, an emulsion, or a gel. As will be appreciated by those skilled in the art, it should be safe for the liquid carrier to be directly applied to the skin wound, and should avoid or limit stimulation or inflammation or the level of pain that rises for the skin.

[0093] In one aspect, the invention provides a kind of dressing comprising any of the compositions described above. In the embodiment of the dressing as described herein, the dressing also comprises a host material. In the embodiment of the dressing as described herein, the host material comprises one or more of hydrogel, hydrocolloid, sponge, fabric (including gauze, bandage, non-woven fabric, abdominal towel, facial mask), artificial skin, pigskin, collagen, gelatin, polysaccharide, chitosan, cellulose, sodium hyaluronate, polylactic acid, poloxamer, chitosan, polyethylene glycol, alginate, activated carbon. In some embodiments of dressings, the host material used comprises non-woven fabrics. In some embodiments of dressings, the host material used comprises a facial mask.

[0094] In another aspect, the present invention provides use of the composition described herein for repairing and protecting topical skin or mucosa.

[0095] In another aspect, the present invention provides for use of a composition as described herein for treating an integumentary wound.

[0096] In another aspect, the present invention provides use of the composition described herein in anti-inflammatory and anti-acne treatment.

[0097] In another aspect, the present invention provides the use of the composition described herein in reducing melanin in the skin. The composition can be used for skin whitening.

[0098] In another aspect, the present invention provides the use of the composition described herein for cosmetic relief in cosmetics.

[0099] In another aspect, the present invention provides use of the composition described herein in a coating in a medical device.

[0100] In another aspect, the present invention provides the use of the composition described herein in improving the stability of mussel mucin in a composition. In some embodiments, the composition can be used to reduce discoloration of a mussel mucin composition. In some embodiments, the composition can be used to maintain the DOPA content in a mussel mucin composition.

[0101] The present invention provides a method for preparing a mussel mucin composition with high stability, and the specific method comprises the following steps:

[0102] Step 1: Prepare the required components, including component one, component two, component three, component four, component five, component six, mussel mucin and pure water.

[0103] Step 2: Mix the purified mussel mucin with component one, component two, component three, component four, component five, component six, and pure water, and mechanically stir to form a uniform system to prepare a stable mussel mucin dressing;

[0104] Step 3: Dispense the solution into suitable containers, seal and sterilize. During the preparation process, care should be taken to maintain a constant temperature to avoid degradation of mussel mucin due to high temperature. In addition, contact with air should be minimized during the preparation process.

[0105] The mussel mucin composition with specific components added in the present invention greatly improves the yellowing and instability of the existing recombinant mussel mucin system, has high biological activity and stability, and a high DOPA retention rate, which is conducive to its application in the fields of medical devices, wound care, etc.

[0106] The preparation method of the mussel mucin dressing of the present invention is simple and easy to operate, and has broad application prospects.

[0107] The invention will now be described in more detail in the following non-limiting examples, with reference to the accompanying drawings, in which:

[0108] Figure 1 The mass ratio (%wt) of dopa to mussel mucin in the compositions of Examples 1 to 8 of the present invention after aging at 60°C for 65 days is shown.

[0109] Example

[0110] The present invention is further described in detail below in conjunction with the examples and drawings. The examples are only used to explain the present invention, but not to limit the scope of the present invention. Those skilled in the art will understand that various changes, modifications, substitutions and deletions can be made without departing from the basic concept of the present invention defined in the claims. For example, other components can also be added to the composition of mussel mucin.

[0111] The following is an example of a method for preparing a stable mussel mucin composition, comprising component one, component two, component three, component four, component five, component six, mussel mucin and water. Component one comprises butylated hydroxytoluene, tert-butylhydroquinone, sodium pyrosulfite and 3-O-ethyl ascorbic acid ether. A blank control group is prepared at the same time, which does not contain component one compared with the preparations described in Examples 1 to 8, and the remaining components are the same, for comparison. The semi-finished product produced is sterilized by irradiation and divided into three batches, which are accelerated aged at 25°C and 60°C, respectively, and taken out and tested after being placed for 65 days.

[0112] Embodiment 1:

[0113] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 0.01g butylated hydroxytoluene (component one), and 0.0013g DL-malic acid (component six).

[0114] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium edetate, butylated hydroxytoluene, DL-malic acid and mussel mucin. Continue stirring until uniformly mixed. After testing the pH value, divide the mixture into containers, seal and sterilize for storage.

[0115] Embodiment 2:

[0116] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 0.04g butylated hydroxytoluene (component one), and 0.0013g DL-malic acid (component six).

[0117] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium edetate, butylated hydroxytoluene, DL-malic acid and mussel mucin. Continue stirring until uniformly mixed. After testing the pH value, divide the mixture into containers, seal and sterilize for storage.

[0118] Embodiment 3:

[0119] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 0.02g tert-butylhydroquinone (component one), and 0.0013g DL-malic acid (component six).

[0120] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium ethylenediaminetetraacetic acid, tert-butylhydroquinone, DL-malic acid and mussel mucin. Continue stirring until it is evenly mixed. After testing the pH value, divide it into containers, seal and sterilize it for storage.

[0121] Embodiment 4:

[0122] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 0.04g tert-butylhydroquinone (component one), and 0.0013g DL-malic acid (component six).

[0123] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium ethylenediaminetetraacetic acid, tert-butylhydroquinone, DL-malic acid and mussel mucin. Continue stirring until it is evenly mixed. After testing the pH value, divide it into containers, seal and sterilize it for storage.

[0124] Embodiment 5:

[0125] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 0.02g sodium metabisulfite (component one), and 0.0013g DL-malic acid (component six).

[0126] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium ethylenediaminetetraacetic acid, sodium metabisulfite, DL-malic acid and mussel mucin. Continue stirring until it is evenly mixed. After testing the pH value, divide it into containers, seal and sterilize it for storage.

[0127] Embodiment 6:

[0128] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 0.05g sodium metabisulfite (component one), and 0.0013g DL-malic acid (component six).

[0129] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium ethylenediaminetetraacetic acid, sodium metabisulfite, DL-malic acid and mussel mucin. Continue stirring until it is evenly mixed. After testing the pH value, divide it into containers, seal and sterilize it for storage.

[0130] Embodiment 7:

[0131] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 0.2g 3-O-ethyl ascorbic acid ether (component one), and 0.0013g DL-malic acid (component six).

[0132] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium ethylenediaminetetraacetic acid, sodium metabisulfite, DL-malic acid and mussel mucin. Continue stirring until it is evenly mixed. After testing the pH value, divide it into containers, seal and sterilize it for storage.

[0133] Embodiment 8:

[0134] Prepare the raw materials: 0.05g mussel mucin, 90g water, 0.7g hydroxyethyl cellulose (component two), 0.05g methylparaben (component three), 2g glycerin (component four), 3g propylene glycol (component four), 2g polyethylene glycol (component four), 2g xylitol (component four), 0.1g disodium ethylenediaminetetraacetic acid (component five), 1g 3-O-ethyl ascorbic acid ether (component one), and 0.0013g DL-malic acid (component six).

[0135] Add hydroxyethyl cellulose to hot water and stir until it becomes a uniform liquid. Gradually add methylparaben, glycerin, propylene glycol, polyethylene glycol, xylitol, disodium ethylenediaminetetraacetic acid, sodium metabisulfite, DL-malic acid and mussel mucin. Continue stirring until it is evenly mixed. After testing the pH value, divide it into containers, seal and sterilize it for storage.

[0136] In the above embodiments, the mussel mucin composition containing specific components has good stability, moisture retention and antioxidant properties, and can be used for wound repair and skin care. The components and proportions in different embodiments can be adjusted according to actual needs.

[0137] Table 1 Combination formula of Example 1 and Example 2 (%wt)

[0138]

[0139] Table 2 Combination formula of Example 3 and Example 4 (%wt)

[0140]

[0141] Table 3 Combination formula of Example 5 and Example 6 (%wt)

[0142]

[0143] Table 4 Combination formula of Example 7 and Example 8 (%wt)

[0144]

[0145] Table 5: Shows the effect of some specific components of the present invention on the color change of mussel mucin composition

[0146]

[0147] Table 6: Shows the effects of some specific components of the present invention on the pH value of mussel mucin composition

[0148]

[0149]

[0150] Embodiment 9:

[0151] The DOPA content in the mussel mucin composition can be determined by the following method, Figure 1 The results of measuring the DOPA content in the compositions described in Examples 1 to 8 after aging at 60° C. for 65 days are shown.

[0152] 1. Experimental principle: Substances containing 3,4-dihydroxyphenylalanine ("DOPA" or "DOPA") structure are yellow under acidic conditions and turn into deep orange when excess alkali is added.

[0153] 2. Reagents and Instruments

[0154] 2.1 Hydrochloric acid solution: Take 0.1 mL of hydrochloric acid and dilute it to 100 mL with pure water.

[0155] 2.2 DOPA standard solution: Weigh 20 mg of DOPA standard and dilute to 100 mL with hydrochloric acid solution. Prepare before use.

[0156] 2.3A Reagent: Take 4.3mL of hydrochloric acid and dilute it to 100mL with pure water.

[0157] 2.4B Reagent: Take 10g of sodium molybdate dihydrate and 10g of sodium nitrite, dissolve them in pure water and make up to 100mL.

[0158] 2.5C Reagent: Take 4.0g of sodium hydroxide and dilute it to 100mL with pure water.

[0159] 2.6 Instruments: UV spectrophotometer (model: UV-2600i)

[0160] 3. Steps

[0161] 3.1 Take 0mL, 0.1mL, 0.5mL, 1.0mL, 1.5mL, 2.0mL, 2.5mL, and 3.0mL of DOPA standard solution respectively, dilute to 10mL with hydrochloric acid solution (2.1), shake well, and set aside.

[0162] 3.2 Take 1 mL of the above standard solution (3.1), add 0.5 mL of reagent A to each test tube, then add 1.5 mL of reagent B and 2 mL of reagent C to each test tube in turn (reagent C should be added within 5 minutes after reagent B is added), and shake well.

[0163] 3.3 Take 1 mL of the sample to be tested and place it in a 10 mL test tube and operate according to the above method. Use tube No. 0 as the blank and use a 1 cm cuvette to measure the absorbance of the prepared standard solution and sample solution at a wavelength of 500 nm.

[0164] Note: If the sample interferes with the colorimetry, centrifuge it at 3000r / min for 10min and take the supernatant for colorimetry.

[0165] 3.4 Make a standard curve with DOPA concentration as the horizontal axis and absorbance as the vertical axis, and then calculate the DOPA content (μg / mL) of the sample based on the measured absorbance of the sample solution.

[0166] The key technical points for preparing a stable mussel mucin composition are as follows:

[0167] Table 5 shows that BHT added in Examples 1 and 2 and sodium pyrosulfite added in Examples 5 and 6 can effectively reduce the color change of the mussel mucin composition, which is significantly improved compared with the control, while tert-butylhydroquinone added in Examples 3 and 4 and 3-O-ethyl ascorbic acid ether added in Examples 7 and 8 are not effective in reducing the color change of the mussel mucin composition. Table 6 shows that BHT added in Examples 1 and 2 and sodium pyrosulfite added in Examples 5 and 6 can effectively stabilize the pH value of the composition, while tert-butylhydroquinone added in Examples 3 and 4 and 3-O-ethyl ascorbic acid ether added in Examples 7 and 8 are not effective in stabilizing the pH value of the composition. Figure 1 It can be explained that the BHT added in Examples 1 and 2 and the sodium metabisulfite added in Examples 5 and 6 can effectively maintain the DOPA content in the mussel mucin composition, which is significantly improved compared with the control, while the tert-butylhydroquinone added in Examples 3 and 4 and the 3-O-ethyl ascorbic acid ether added in Examples 7 and 8 are not effective in maintaining the DOPA content in the mussel mucin composition.

[0168] In summary, only specific components can slow down the discoloration of the mussel mucin composition and maintain the DOPA content in the composition. Selecting specific components as auxiliary materials in the mussel mucin composition can effectively resist the damage of free radicals, extend the service life of the preparation, and prevent its degradation and deterioration. Selecting appropriate auxiliary materials and addition amounts are important links in improving the stability of the preparation.

[0169] The optimized formulation is shown in the examples, and the mussel mucin has good compatibility with other components, improving the stability and safety of the formulation. Among them, specific components (such as butylated hydroxytoluene or sodium metabisulfite) can extend the service life of the formulation and maintain the biological activity of the mussel mucin.

[0170] The experimental results show that by using the specific components provided by the present invention, such as butylated hydroxytoluene or sodium metabisulfite, the degree of DOPA oxidation of mussel mucin is significantly reduced, the color change of the preparation is significantly reduced, and the stability is significantly improved.

[0171] The invention effectively improves the stability of mussel mucin by selecting different components, etc., and provides a guarantee for its wide application in the fields of medicines and medical devices.

[0172] All references and published patents mentioned herein are hereby incorporated by reference in their entirety.

Claims

1. A composition containing mussel mucin, the composition comprising: a) 0.01 to 10%wt of mussel mucin; b) 0.01 to 0.3%wt of component one, component one is selected from butylated hydroxytoluene (BHT) or sodium metabisulfite; and c) Water.

2. A stable composition containing mussel mucin, the composition comprising: a) 0.01 to 10%wt of mussel mucin; b) 0.01 to 0.3%wt of component one, component one is selected from sodium metabisulfite, butylated hydroxytoluene (BHT), or a combination of the two; and c) water; The composition has one or more of the following characteristics: i) After being stored at 25°C in a sealed container for three months, the appearance remains colorless; or ii) maintaining a DOPA content in the mussel mucin of 1.2 times or more the DOPA content in the control preparation not containing the component 1 after storage at 25°C for three months.

3. The composition of claim 1 or 2, further comprising 0 to 3.0%wt of component 2, wherein component 2 is selected from one or more of polyvinyl alcohol, xanthan gum, carbomer, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxymethylcellulose, and hydroxyethylcellulose.

4. The composition of claim 1 or 2, further comprising 0.01 to 0.4%wt of component three, wherein component three is selected from one or more of benzyl alcohol, p-hydroxybenzoate, ethyl hydroxybenzoate, dimethyl fumarate, and lower fatty acid esters.

5. The composition of claim 1 or 2, further comprising 1 to 20%wt of component four, wherein component four is selected from one or more of glycerol, propylene glycol, sorbitol, glycerol, xylitol, and polyethylene glycol.

6. The composition of claim 1 or 2, further comprising 0.01 to 0.3%wt of component five, wherein component five is selected from one or more of low molecular weight dextran, ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate, and sodium calcium ethylenediaminetetraacetate.

7. The composition of any one of claims 1 or 2, further comprising 0.0001 to 0.3%wt of component six, wherein component six is ​​selected from one or more of boric acid, acetic acid, pyruvic acid, citric acid, sorbic acid, DL-malic acid, DL-tartaric acid, vanillic acid, coumaric acid, gallic acid, disodium bicarbonate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and sodium hydroxide.

8. A composition containing mussel mucin, the composition comprising: a) 0.01 to 0.3%wt of component 1, wherein component 1 is selected from sodium metabisulfite, butylated hydroxytoluene, or a combination of the two; b) 0 to 3.0%wt of component 2, component 2 is selected from one or more of polyvinyl alcohol, xanthan gum, carbomer, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxymethylcellulose, and hydroxyethylcellulose; c) 0.01 to 0.4%wt of component three, wherein component three is selected from one or more of benzyl alcohol, p-hydroxybenzoate, ethyl hydroxybenzoate, dimethyl fumarate, and lower fatty acid esters; d) 1 to 20%wt of component four, component four is selected from one or more of glycerol, propylene glycol, sorbitol, glycerol, xylitol, and polyethylene glycol; e) 0.01 to 0.3%wt of component five, wherein component five is selected from one or more of low molecular weight dextran, ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate, and sodium calcium ethylenediaminetetraacetate; f) 0.0001 to 0.3%wt of component six, wherein component six is ​​selected from one or more of boric acid, acetic acid, pyruvic acid, citric acid, sorbic acid, DL-malic acid, DL-tartaric acid, vanillic acid, coumaric acid, gallic acid, disodium bicarbonate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and sodium hydroxide; g) 0.01 to 10%wt mussel mucin; and h) Water.

9. The composition according to any one of claims 1, 2 or 8, wherein Component one contains BHT.

10. The composition according to any one of claims 1, 2 or 8, wherein Component one comprises sodium metabisulfite.

11. The composition according to any one of claims 1, 2 or 8, wherein The composition comprises 0.01 to 5%wt of mussel mucin.

12. The composition according to any one of claims 1, 2 or 8, wherein The composition comprises 0.01 to 1%wt of mussel mucin.

13. The composition according to any one of claims 1, 2 or 8, wherein The composition comprises 0.01 to 0.1%wt of mussel mucin.

14. The composition according to any one of claims 1, 2 or 8, wherein The composition comprises 0.05%wt of mussel mucin.

15. The composition according to any one of claims 1, 2 or 8, wherein The composition comprises 0.01 to 0.2 wt% of component one.

16. The composition of any one of claims 1, 2 or 8, wherein The composition comprises 0.01 to 0.08 wt% of component one.

17. The composition of any one of claims 1, 2 or 8, wherein The composition comprises 0.01 to 0.1 wt% of component one.

18. The composition of any one of claims 1, 2 or 8, wherein The composition comprises 0.01 to 0.05 wt% of component one.

19. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 100:1 to 1:

100.

20. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 50:1 to 1:

50.

21. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 20:1 to 1:

20.

22. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 10:1 to 1:

20.

23. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 5:1 to 1:

20.

24. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 5:1 to 1:

10.

25. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 5:1 to 1:

5.

26. The composition of any one of claims 1, 2 or 8, wherein The wt / wt ratio of mussel mucin to component one is 5:1 to 1:

1.

27. The composition of claim 3 or 8, wherein Component two comprises hydroxyethyl cellulose.

28. The composition of claim 26, wherein The composition comprises 0.7%wt of component two.

29. The composition of claim 4 or 8, wherein Component three contains parabens.

30. The composition of claim 29, wherein The composition comprises 0.05%wt of component three.

31. The composition of claim 5 or 8, wherein Component four contains glycerin, propylene glycol, xylitol, and polyethylene glycol.

32. The composition of claim 30, wherein The composition comprises 9%wt of component four.

33. The composition of claim 6 or 8, wherein Component five contains disodium EDTA.

34. The composition of claim 33, wherein The composition comprises 0.1%wt of component five.

35. The composition of claim 7 or 8, wherein Component six contained 0.0013% wt DL-malic acid.

36. The composition of any one of claims 1, 2 or 8, further comprising 0.01 to 0.5%wt of component seven, wherein component seven is selected from one or more of polysorbate 80, calcium stearate, aluminum monostearate, dimethicone, disodium hydrogen phosphate dodecahydrate, dipotassium hydrogen phosphate trihydrate, soybean lecithin, sodium alginate, poloxamer, polysorbate 20, egg yolk lecithin, gum arabic, caprylic and capric mono- and di-glycerides, oleic acid, mono- and di-stearic glycerides, potassium stearate, sodium citrate, sodium stearate, sorbitan oleate (Span 80), polyoxyethylene 35 castor oil, cetostearyl alcohol, lanolin, octadecyl alcohol, hexadecanol, and cholesterol.

37. The composition of any one of claims 1, 2 or 8, wherein The composition further comprises 0.0001 to 0.3%wt of component eight, wherein component eight is selected from one or more of carotene, chlorophyll, lutein ester, and lutein.

38. The composition of any one of claims 1, 2 or 8, wherein The pH of the composition is 3.0 to 7.

0.

39. The composition of any one of claims 1, 2 or 8, wherein The pH of the composition is between 3.5 and 5.

0.

40. The composition of any one of claims 1, 2 or 8, wherein The mussel mucin is synthetic mussel mucin, recombinant mussel mucin, or is extracted from mussels.

41. The composition of any one of claims 1, 2 or 8, wherein The mussel mucin is derived from Mytilusedulis, Mytilus galloprovincialis, Mytlilus coruscus, Perna viridis, Mytlilus californianus, or Limnoperna fortune.

42. The composition of any one of claims 1, 2 or 8, wherein The mussel mucin comprises one or more of Mfp-1, Mfp-2, Mfp-3, Mfp-4, Mfp-5, and Mfp-6.

43. The composition of any one of claims 1, 2 or 8, wherein Mussel mucin contains one or more of Mefp-1, Mefp-2, Mefp-3, Mefp-4, Mefp-5, Mefp-6, Mcfp-1, Mcfp-2, Mcfp-3, Mcfp-4, Mcfp-5, Mcfp-6, Mgfp-1, Mgfp-2, Mgfp-3, Mgfp-4, Mgfp-5, Mgfp-6, Mufp-1, Mufp-2, Mufp-3, Mufp-4, Mufp-5, Mufp-6.

44. The composition of any one of claims 1, 2 or 8, wherein The mussel mucin comprises fused mussel mucin, wherein the fused mussel mucin comprises one or more of FP-131, FP-151 and FP-153.

45. The composition of any one of claims 1, 2 or 8, wherein The composition has one or more of the following characteristics: i) After being stored at 60°C in a sealed container for 65 days, the appearance remains colorless or light yellow; or ii) maintaining a DOPA content in the mussel mucin of 1.5 times or more the DOPA content in the control preparation not containing the component 1 after storage at 60°C for 65 days.

46. ​​A topical formulation comprising the composition of any one of claims 1 to 45.

47. The topical formulation of claim 46, wherein The topical formulation is a solution, hydrogel, cream, paste, lotion, ointment, foam, serum, or moisturizer.

48. The topical formulation of claim 46 or 47, wherein The topical formulations are applied to the skin.

49. A dressing comprising the composition of any one of claims 1 to 45.

50. The dressing of claim 49, further comprising a matrix material.

51. The dressing of claim 50, wherein the matrix material comprises a hydrogel, a hydrocolloid, a sponge, a fabric, and the fabric comprises one or more of gauze, a band-aid, a non-woven fabric, a facial mask, artificial skin, pig skin, collagen, gelatin, polysaccharides, chitosan, cellulose, sodium hyaluronate, polylactic acid, poloxamer, chitosan, polyethylene glycol, alginate, and activated carbon.

52. Use of the composition of claims 1-45 in the preparation of a topical preparation for repairing and protecting the skin or mucosa.

53. Use of the composition of claims 1-45 in the preparation of a preparation for treating an integumentary wound.

54. Use of the composition of claims 1-45 in the preparation of an anti-inflammatory and anti-acne preparation.

55. Use of the composition of claims 1-45 in the preparation of a preparation for reducing melanin in the skin.

56. Use of the composition of claims 1-45 in cosmetics for cosmetic soothing.

57. Use of the composition of claims 1-45 in a coating in a medical device.

58. Use of the composition of claims 1-45 for improving the stability of mussel mucin in a composition.

Images